A population-based assessment of the impact of 7- and 13-valent pneumococcal conjugate vaccines on macrolide-resistant invasive pneumococcal disease: Emergence and decline of streptococcus pneumoniae serotype 19a (cc320) with dual macrolide resistance mechanisms
Clinical Infectious Diseases
September 06, 2017
Schroeder MR, et al.
This study assessed the impact of heptavalent pneumococcal conjugate vaccine (PCV7) and PCV13 on macrolide-resistant invasive pneumococcal disease (MR-IPD). As per findings, the selective pressures of widespread macrolide use and PCV7 and PCV13 introductions on S. pneumoniae were associated with changes in macrolide resistance and the molecular basis over time in the study population. Durable surveillance and programs that emphasize the judicious use of antibiotics need to continue to be a focus of public health strategies directed at S. pneumoniae.
Your browser is currently blocking ads. We depend on ad sponsorships in order to keep this site free to the healthcare provider community. Help us keep this site free by turning off your ad blocker.
Turn Off Ad Blocker
We have detected that you are currently blocking ads. We kindly ask that you enable ads when visiting our site. We depend on ad sponsorships in order to keep this site free to the healthcare provider community.